Circulation: Heart Failure

SEPTEMBER 27, 2023

Mediation of the association between MMP-2 and HF was assessed by censoring participants who developed AF or coronary heart disease before HF. 1.81]), incident HF with preserved ejection fraction (1.44 [95% CI, 1.07–1.94]), 1.94]), incident heart failure with reduced ejection fraction (1.48 [95% CI, 1.08–2.02]),

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Heart Disease 40

HeartRhythm

SEPTEMBER 4, 2024

Recent data suggest that sodium-glucose contransporter-2 inhibitors (SGLT2i) may mitigate development of cardiac arrythmias in patients with heart failure with preserved ejection fraction and patients with ischemic heart disease [1].

Preserved Ejection Fraction 40

Preserved Ejection Fraction Outcomes Heart Failure Cardiomyopathy 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

Patients diagnosed with reduced ejection fraction (HFrEF) and with heart failure with mildly reduced ejection fraction (HFmrEF) were treated with Vericiguat combined with “ARNI, BB, MRA, SGLT2i” therapy. vs. 43.1 ± 8.5%, P < 0.01), LVEDD (60.5 ± 8.1 vs. 58.2 ± 7.3 mm, mm, P < 0.01), NT-proBNP (4,567.8 ± 5,163.9

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

Open Heart

APRIL 24, 2024

HF with preserved ejection fraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3% Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). and 29.2%, p<0.001).

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

Dr. S. Venkatesan MD

APRIL 18, 2024

Lowering the raised LA mean pressure is a major therapeutic goal in any severely symptomatic left heart disease, whether it is valvular or myocardial disease. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Congenital Heart Disease VSD 40

Journal of the American Heart Association

JANUARY 19, 2024

Journal of the American Heart Association, Ahead of Print. BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. In 10 019 middle‐aged individuals (mean age, 63.3±10.6

Heart Failure 45

Heart Failure Preserved Ejection Fraction Hospital Heart Disease 45

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

European Journal of Heart Failure

APRIL 10, 2025

Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. The effect of finerenone according to glycaemic status (i.e.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Diabetes Cardiomyopathy 40

Science Daily - Heart Disease

SEPTEMBER 2, 2024

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.

Preserved Ejection Fraction 123

Preserved Ejection Fraction Heart Failure Hospital 123

Science Daily - Heart Disease

MARCH 26, 2025

Compared with those who spent most of their time in a single room, people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a new study.

Heart Failure 62

Heart Failure Preserved Ejection Fraction Outcomes Hospital 62

Circulation

NOVEMBER 11, 2024

Background:SGLT2 inhibitors have demonstrated efficacy in reducing cardiovascular death and hospitalization and are recommended as first-line therapy for hear failure (HF) in adults due to acquired heart diseases. We excluded articles related to acute decompensated HF and HF with preserved ejection fraction.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Disease Preserved Ejection Fraction 40

DAIC

APRIL 2, 2024

The results showed that people who used e-cigarettes at any point were 19% more likely to develop heart failure compared with people who had never used e-cigarettes. The researchers also found no evidence that participants’ age, sex or smoking status modified the relationship between e-cigarettes and heart failure.

Heart Failure 105

Heart Failure Preserved Ejection Fraction Research Risk Factors 105

DAIC

JUNE 26, 2024

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

DAIC

APRIL 9, 2024

HCM is the most common genetic heart disease worldwide and is estimated to affect 1 in 500 people. It causes the heart muscle to become stiff and thick, making it harder for the heart to pump blood properly and increasing the risk of sudden cardiac death. These data strongly support moving on to phase 3 development.”

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Obesity, body composition and cardiorespiratory fitness in heart failure with preserved ejection fraction.”

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Journal of the American Heart Association

MARCH 13, 2025

Outcomes (allcause, cardiovascular, and noncardiovascular death; allcause and HF hospitalizations) were assessed by univariable and multivariable Cox regressions with EF modeled as a spline.

Preserved Ejection Fraction 70

Preserved Ejection Fraction Heart Failure Peripheral Arterial Disease Cardiomyopathy 70